Prospecto: information for the user
Meropenem Qilu 500mg powder for injectable solution and for EFG infusion
Read this prospect carefully before starting to use this medicine, because it contains important information for you.
-This medicine has been prescribed only to you, and you must not give it to other people even if they have the same symptoms as you, as it may harm them.
1. What isMeropenem Qiluand for what it is used
2. What you need to know before starting to useMeropenem Qilu
3. How to useMeropenem Qilu
4. Possible adverse effects
5. Storage ofMeropenem Qilu
6. Contents of the package and additional information
Meropenem Qilu contains the active ingredient meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by destroying bacteria that can cause serious infections.
Meropenem Qilu is used to treat the following infections in adults and children aged 3 months and above:
This medicine may be used to treat neutropenic patients (with a weakened immune system) who present fever suspected to be due to bacterial infection.
Meropenem Qilu can be used to treat bacterial blood infection that may be associated with one of the infections mentioned above
Do not use Meropenem Qilu
Warnings and precautions
Consult your doctor or pharmacist before starting to use Meropenem Qilu
Blood tests
You may develop a positive result on a test (Coombs test) indicating the presence of antibodies that can destroy red blood cells.
Your doctor will discuss this with you.
Skin reactions
You may develop signs and symptoms of severe skin reactions (see section 4). If this occurs, inform your doctor or nurse immediately so that they can treat the symptoms.
If you are in any of these situations, or if you have doubts, consult your doctor before using this medication.
Other medications and Meropenem Qilu
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This is because Meropenem Qilu may affect the way some medications work, and some of these may have an effect on Meropenem Qilu.
Particularly, inform your doctor or nurse if you are taking any of the following medications:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
It is preferable to avoid the use of meropenem during pregnancy.
Your doctor will decide if you should use Meropenem Qilu.
It is essential to inform your doctor if you are breastfeeding or intend to breastfeed before receiving Meropenem Qilu. Small amounts of this medication pass into breast milk. Therefore, your doctor will decide if you should use meropenem during breastfeeding.
Driving and operating machinery
No studies have been conducted on the effects on the ability to drive and operate machinery.
However, meropenem has been associated with headaches and tingling or prickling sensations in the skin (paresthesia). Either of these effects could affect your ability to drive or operate machinery.
This medication may cause involuntary muscle movements, leading to rapid and uncontrolled bodily agitation (convulsions), which is usually accompanied by loss of consciousness. Do not drive or operate machinery if you experience this side effect.
Meropenem Qilu contains sodium
This medication contains 45mg of sodium (main component of table salt/for cooking) in each 500mg dose. This is equivalent to 2.25% of the recommended daily maximum sodium intake for an adult.
If you have a situation that requires controlling your sodium intake, inform your doctor, pharmacist, or nurse.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist or nurse.
Use in adults
Use in children and adolescents
The dose for children over 3 months and up to 12 years is decided using the child's age and weight. The normal dose is between 10 mg and 40 mg of meropenem per kilogram (kg) of the child's weight. You will normally be given a dose every 8 hours. Children weighing over 50 kg will be given an adult dose.
How to use Meropenem Qilu
If you use more Meropenem Qilu than you should
If you accidentally use more doses than prescribed, contact your doctor or go to the nearest hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to use Meropenem Qilu
If you forget a dose, you should receive it as soon as possible. However, if it is almost time to administer the next dose, do not receive the missed one. Do not use a double dose (two injections at once) to compensate for a missed dose.
If you interrupt the treatment with Meropenem Qilu
Do not stop Meropenem Qilu until your doctor tells you to.
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe allergic reactions
If you experience any of the following symptoms, inform your doctor or nurse immediately. You may need urgent medical treatment. The symptoms may include a sudden onset of:
Blood cell damage
The symptoms include:
If you notice any of the above, seek medical attention immediately.
Possible side effects
Frequent (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a side effect that does not appear in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the vial label after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
After reconstitution/dilution:
Administration of intravenous injection in bolus
A solution for intravenous injection in bolus is prepared by dissolving the medication in injection water, to a final concentration of 50mg/ml.
The reconstituted solution of the medicinal product in injection water must be used immediately.
Administration by intravenous infusion
A solution for infusion is prepared by dissolving the medication in a 9mg/ml sodium chloride (0.9%) solution, or in a 50mg/ml dextrose (5%) solution, to a final concentration of 1 to 20mg/ml.
The reconstituted solution of the medication in 9mg/ml sodium chloride (0.9%) solution must be used immediately. The maximum time that should elapse between the start of reconstitution and the end of infusion should not exceed one hour.
The reconstituted solution of the medication in 50mg/ml dextrose (5%) solution must be used immediately.
Do not freeze the reconstituted solution.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Meropenem Qilu
The active ingredient is meropenem.
Each vial contains 500 mg of meropenem (in the form of meropenem trihydrate).
The other component is sodium carbonate.
Appearance of Meropenem Qilu and packaging contents
Meropenem Qilu is presented in vials containing a white or slightly yellowish powder for injectable or infusion solution.
Packaging sizes: 1 vial or 10 vials (clinical packaging).
Only some packaging sizes may be commercially available.
Marketing authorization holder and manufacturer
Marketing authorization holder
QILU PHARMA SPAIN S.L.
Paseo de la Castellana 40, 8th floor,
28046 Madrid,
Spain
Manufacturing
KYMOS, S.L.
Ronda de Can Fatjó,
7B (Parque Tecnológico del Vallès),
Cerdanyola del Vallès,
08290 Barcelona,
Spain
Eurofins Analytical Services Hungary Kft.
Anonymus utca 6, Budapest
H-1045,
Hungary
LLC “UNIFARMA”
Vangazu street 23,
Riga, LV-1024,
Latvia
Local representative:
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya, 53-55
08007 – Barcelona
Spain
Tel.: +34 93 342 7890
This medicine is authorized in the member states of the European Economic Area with the following names:
Member state name | Medicine name |
Germany | Meropenem Qilu 500 mg Powder for the preparation of an injection/infusion solution |
Denmark | Meropenem Qilu |
Finland | Meropenem Qilu 500 mg injection-/infusion-dry substance for solution |
Hungary | Meropenem Qilu 500 mg for oldatos injection/infusion |
Italy | Meropenem Qilu |
Norway | Meropenem Qilu |
Spain | Meropenem Qilu 500 mg powder for injectable and infusion solution EFG |
Sweden | Meropenem Qilu 500 mg powder for injection-/infusion liquid, solution |
Last review date of this leaflet: 12/2023
Other sources of information:
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.